The estimated Net Worth of Tamara L Joseph is at least $615 Thousand dollars as of 1 February 2024. Ms. Joseph owns over 30,906 units of Millendo Therapeutics stock worth over $563,512 and over the last 11 years she sold MLND stock worth over $50,990. In addition, she makes $0 as General Counsel and Corporate Secretary at Millendo Therapeutics.
Sign up
Ms. Joseph MLND stock SEC Form 4 insiders trading
Tamara has made over 3 trades of the Millendo Therapeutics stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 30,906 units of MLND stock worth $42,341 on 1 February 2024.
The largest trade she's ever made was selling 30,906 units of Millendo Therapeutics stock on 1 February 2024 worth over $42,341. On average, Tamara trades about 2,582 units every 26 days since 2014. As of 1 February 2024 she still owns at least 531,615 units of Millendo Therapeutics stock.
You can see the complete history of Ms. Joseph stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tamara Joseph biography
Tamara L. Joseph J.D. serves as General Counsel, Corporate Secretary of the Company. Ms. Joseph was appointed as our General Counsel and Corporate Secretary in August 2019, and leads our legal, compliance and human resource departments. Ms. Joseph has led legal, compliance, public and government affairs, and risk management departments at life science companies in the United States and in Europe for over 20 years. From June 2018 to August 2019, she served as General Counsel of Enzyvant Therapeutics. From March 2014 to February 2018, she served as General Counsel of InVivo Therapeutics, after consulting for InVivo Therapeutics from September 2013 to February 2014. From 2008 to 2012, she served as General Counsel of Cubist Pharmaceuticals. From 2006 to 2008, she served as Executive Vice President, General Counsel of Mayne Pharma (later acquired by Hospira). She served as General Counsel of Transkaryotic Therapies (later acquired by Shire) during 2005. From 1998 to 2005, she served as Vice President, International Legal, of Biogen Idec, leading the legal department’s operations outside the United States. Ms. Joseph is also a member of the board of directors and executive and governance committees of Heluna Health, a population health non-profit with a focus on child and maternal nutrition. Ms. Joseph has a B.A. in Economics from Duke University, a J.D. from the University of Michigan, and LL.M. degrees from the College of Europe in Belgium and the University of Paris.
How old is Tamara Joseph?
Tamara Joseph is 57, she's been the General Counsel and Corporate Secretary of Millendo Therapeutics since 2019. There are 8 older and 5 younger executives at Millendo Therapeutics. The oldest executive at Millendo Therapeutics, Inc. is John Howe, 77, who is the Independent Director.
What's Tamara Joseph's mailing address?
Tamara's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
What does Millendo Therapeutics do?
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
What does Millendo Therapeutics's logo look like?
Complete history of Ms. Joseph stock trades at InVivo Therapeutics Corp, Spero Therapeutics Inc, and Millendo Therapeutics
Millendo Therapeutics executives and stock owners
Millendo Therapeutics executives and other stock owners filed with the SEC include:
-
Julia Owens,
President, Chief Executive Officer, Director -
Louis Arcudi,
Chief Financial Officer -
Ryan Zeidan,
Chief Development Officer -
Dr. Julia C. Owens Ph.D.,
Exec. Chair of Board -
Louis J. Arcudi III, M.B.A., MBA,
CEO, Pres & Director -
Carol Gallagher,
Independent Chairman of the Board -
Connie Chang,
Vice President - Corporate Affairs -
Carole Nuechterlein,
Independent Director -
John Howe,
Independent Director -
James Hindman,
Independent Director -
Mary Hedley,
Independent Director -
Habib Dable,
Independent Director -
Geoffrey Nichol,
Independent Director -
Thomas Hoover,
Chief Commercial Officer -
Christophe Arbet-Engels,
Chief Medical Officer -
Tamara Joseph,
General Counsel, Corporate Secretary -
Denise Dorigo Jones,
VP of HR -
Jeffery M. Brinza J.D.,
Interim Gen. Counsel -
Jennifer Lynn Minai-Azary,
CFO & Principal Accounting Officer -
Jeffery M. Brinza,
Sec., CAO and General Counsel -
Randall W Whitcomb,
Director -
Pharis Mohideen,
Chief Medical Officer -
Jennifer Lynn Minai Azary,
Chief Financial Officer